Phase 1a/1b Open Label Dose-escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Pembrolizumab (Primary) ; TPST 1495 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors Tempest Therapeutics

12 Nov 2024 According to a Tempest Therapeutics media release, company expects to disclose data from the TPST-1495 Phase 1 combination arm in patients with advanced endometrial cancer in 2025.
16 Oct 2024 Planned End Date changed from 1 Oct 2024 to 1 Dec 2024.
16 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Nov 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com